Products

HUMIRA (adalimumab injection)

^PrHUMIRA^®  is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 13 to 17 years of age weighing ≥40 kg with severely active CD and/or who have had an inadequate response or were intolerant to conventional therapy (a corticosteroid and/or aminosalicylate and/or an immunosuppressant) and/or a tumour necrosis factor-alpha antagonist.
 

^PrHUMIRA^®  is indicated for inducing and maintaining clinical remission in pediatric patients 5 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy including corticosteroids and/or azathioprine or 6-mercaptopurine or who are intolerant to such therapies.